查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126534

類風濕性關節炎診斷：市場洞察、競爭格局和市場預測 - 2034年

Rheumatoid Arthritis Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

概述：

  • 2025年類風濕性關節炎診斷市場規模估計為 31.5億美元，預計到2034年將達到 56.5億美元。該成長是由類風濕性關節炎在全球範圍內的患病率上升、臨床上向早期和準確的血清學診斷轉變以及臨床檢查室中基於免疫檢測測定的自身抗體檢測的自動化程度不斷提高所推動的。
  • 全球類風濕性關節炎診斷市場預計在2026年至2034年的預測期內將以 6.7%的CAGR成長。
  • 就診斷測試而言，類風濕因子（RF）檢測領域到2025年佔 38%的佔有率，推動類風濕性關節炎診斷市場的發展。
  • 依技術分類，免疫檢測領域引領類風濕性關節炎診斷市場，到2025年佔 41%的市場佔有率。
  • 就疾病進展階段而言，「已確診類風濕性關節炎」細分市場在2025年引領市場，佔類風濕性關節炎診斷市場的64%。
  • 依檢體類型分類，「血液/血清」區隔到2025年佔市場佔有率的78%，引領類風濕性關節炎診斷市場。
  • 依最終用戶分類，到2025年，診斷檢查室領域引領類風濕性關節炎診斷市場，佔 39%的市場佔有率。
  • 到2025年，北美以 40%的銷售額引領全球類風濕性關節炎診斷市場，在全球區域市場佔有率中佔據最高地位。

類風濕性關節炎的診斷包括血清學、生化和後續觀察檢查，用於檢測、確診和監測類風濕性關節炎是一種慢性自體免疫疾病，其特徵是關節發炎、滑膜損傷，如不治療，進行性性功能障礙。由於目前尚無單一的類風濕性關節炎確診檢測方法，因此診斷主要依據臨床評估，並結合類風濕因子、抗環瓜氨酸肽抗體、C反應蛋白和紅血球沉積速率等實驗室指標的解讀，以及影像學和身體檢查結果。該市場按診斷測試類型（例如，類風濕因子檢測、抗環瓜氨酸肽抗體檢測、C反應蛋白檢測、紅血球沉積速率檢測）、技術（例如，免疫檢測、酵素免疫分析法、化學冷光免疫檢測、乳膠凝集測試）、疾病階段（早期和確診類類風濕性關節炎）以及檢體類型（例如，血液/血清、血漿、滑液）細分。此外，就最終用戶而言，醫院、診所、診斷檢查室和風濕病專科診所是主要組成部分。由於該疾病的盛行率不斷上升，人們越來越重視早期診斷以防止不可逆的關節損傷，以及利用高通量免疫檢測和化學冷光平台實現自身抗體檢測的自動化，類風濕性關節炎的診斷已成為全球風濕病學和自體免疫疾病檢測連續體中的一個重要組成部分。

類風濕性關節炎診斷市場的主要市場促進因素

  • 類風濕性關節炎的盛行率在全球呈現上升趨勢，據估計，全球約有0.5%至1.0%的成年人口受到影響。該病在女性中尤其常見，這使得可診斷和檢測的患者群體不斷擴大。
  • 隨著臨床上對早期診斷的重視程度日益提高，抗CCP抗體檢測的應用也日益廣泛。此檢測對類風濕性關節炎具有很高的特異性，使得在發生不可逆的關節侵蝕之前開始治療成為可能。
  • 診斷試劑製造商日益擴大其多重和自動化自體免疫檢測板的範圍，例如Abbott的多重自體免疫檢測板，該檢測板可同時檢測 12 種自體抗體，於2025年 10月獲得 FDA 批准。這提高了檢測的全面性和檢查室效率。
  • 臨床檢查室中免疫檢測和化學冷光平台的自動化程度不斷提高，減少類風濕因子和抗CCP抗體檢測所需的時間，並擴大檢測能力。
  • 由於監管部門的批准和領先診斷製造商的產品系列，自體免疫血清學檢測的可用性日益擴大，例如Roche在2026年 1月擴展了其自身免疫檢測平台，以及Thermo Fisher Scientific在2026年 6月獲得了 FDA 510（k）對 EliA CTD 13 篩檢檢測的批准。
  • 隨著風濕病專家和基層醫療醫師對複合.血清學檢測價值的認識不斷提高，加上針對自體免疫檢測組合的醫保覆蓋範圍擴大，已開發國家和新興市場對此類檢測的使用量正日益增加。
  • 受疾病負擔加重、技術自動化和診斷產品組合不斷擴大的推動，預計該市場將保持穩定成長至2034年。

推動類風濕性關節炎診斷市場成長的因素

市場促進因素

全球類風濕性關節炎盛行率不斷上升

類風濕性關節炎診斷市場最持續的促進因素是全球疾病負擔的持續加重。據估計，類風濕性關節炎影響全球0.5%至1.0%的成年人口，其中女性約佔確診病例的四分之三。此外，由於全球人口老化和疾病認知度的提高，盛行率持續上升。隨著越來越多的患者出現關節疼痛、僵硬和腫脹等症狀，基層醫療醫生和風濕症醫師擴大使用血清學檢測，包括類風濕因子和抗CCP抗體檢測，以確診並將類風濕性關節炎與其他發炎性和退化性關節疾病區分開來。由於目前尚無單一的類風濕性關節炎確診檢測方法，診斷檢查室通常會進行包含多種標記的聯合檢測，這進一步增加了檢測的數量。隨著全球疾病盛行率在2034年之前持續上升，診斷檢測的目標族群將直接擴大，支持市場的持續成長。

越來越重視早期準確診斷

早期診斷的結構性轉變是該市場的主要成長動力。臨床指引日益強調，早期發現和治療類風濕性關節炎（理想情況下在症狀出現後的數月內）可顯著降低不可逆關節侵蝕和長期功能障礙的風險。抗環瓜氨酸肽抗體檢測具有高度特異性，可在臨床症狀完全出現前數年呈陽性，在早期檢測策略中發揮核心作用，並且擴大與類風濕因子檢測聯合使用，以提高診斷的準確性。風濕症醫師和基層醫療醫生正逐漸採用聯合血清學檢測而非單一標記檢測，以減少疾病早期階段的假陰性結果。隨著醫療保健系統繼續優先考慮早期療育以降低與殘疾和關節重建相關的長期成本，預計在整個預測期內，對高靈敏度和高特異性診斷檢測的需求將相應成長。

市場限制因素

儘管預期類風濕性關節炎診斷市場將保持穩定成長，但仍面臨許多限制因素。由於目前尚無針對類風濕性關節炎的單一確診檢測方法，因此沒有任何單一生物標記能夠同時具備完全的敏感性和特異性。類風濕因子也存在於其他自體免疫疾病患者和健康個體中，導致假陽性結果；而抗CCP抗體雖然特異性很高，但在疾病早期階段可能缺乏敏感性，需要進行更昂貴的綜合檢測和臨床相關性評估。類風濕性關節炎的早期症狀與其他發炎性和退化性關節疾病的症狀重疊，因此延遲診斷仍然很常見。此外，在許多地區，特別是農村和資源匱乏地區，風濕症醫師資源有限。自動化多重檢測和化學冷光平台的高成本阻礙了小規模檢查室和價格敏感型新興市場對這些檢測方法的採用，而主要發達市場以外地區對高級自體免疫檢測組合的保險償付不一致也限制了這些檢測方法的應用。對比診斷研究表明，不同廠商生產的抗CCP抗體和類風濕因子檢測產品的性能差異很大，導致結果解讀和檢查室間標準化困難。儘管疾病盛行率上升和對早期診斷的日益重視等強勁的潛在促進因素，但診斷準確性、可及性、成本和標準化方面的這些障礙共同導致市場成長放緩。

目錄

第1章 類風濕性關節炎診斷市場：引言

  • 調查範圍
  • 市場區隔
  • 市場先決條件

第2章 類風濕性關節炎診斷市場：執行摘要

  • 市場概覽

第3章 類風濕性關節炎診斷市場：關鍵因素分析

  • 類風濕性關節炎診斷市場：市場促進因素
    • 類風濕性關節炎的全球盛行率上升。
    • 越來越重視早期準確診斷
    • 免疫檢測平台的自動化
    • 監管批准和產品系列擴展
  • 類風濕性關節炎診斷市場：限制與挑戰
    • 目前尚無單一的確診測試。
    • 診斷延遲和專科醫生資源有限
    • 成本和還款限制
  • 類風濕性關節炎診斷市場：市場機會
    • 連接複用和自動化檢測面板的擴展
    • 新興市場診斷檢查室的擴張

第4章 人工智慧、地緣政治、貿易與經濟趨勢

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 波特五力分析

第7章 類風濕性關節炎診斷市場：評估

  • 通過診斷測試
    • 類風濕因子（RF）檢測
    • 抗環瓜氨酸肽（抗CCP）抗體檢測
    • C反應蛋白（CRP）檢測
    • 紅血球沉積速率（ESR）檢測
    • 其他
  • 依技術
    • 免疫檢測
    • 酵素免疫分析法（ELISA）
    • 化學冷光免疫檢測（CLIA）
    • 乳膠凝集測試
  • 依疾病階段
    • 早期類風濕性關節炎
    • 已確診的類風濕性關節炎
  • 依樣本類型
    • 血液/血清
    • 血漿
    • 滑液
  • 依最終用戶
    • 醫院和診所
    • 診斷實驗室
    • 風濕病專科診所
  • 依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章 類風濕性關節炎診斷市場：競爭格局

  • 市場集中度與結構
  • 競爭定位與市場佔有率分析（加值服務）

第9章 類風濕性關節炎診斷市場：新創企業資金籌措與投資趨勢

第10章 類風濕性關節炎診斷市場：公司概況與產品概況

  • Abbott Laboratories
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Beckman Coulter
  • Werfen
  • Svar Life Science
  • Orgentec Diagnostika
  • EUROIMMUN

第11章 KOL的觀點

第12章 專案方法

第13章 關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0998

Rheumatoid Arthritis Diagnostics Market Summary

Overview:

  • The Rheumatoid Arthritis Diagnostics market is estimated at USD 3.15 billion in 2025 and is projected to reach USD 5.65 billion by 2034. Growth is anchored in the rising global prevalence of rheumatoid arthritis, the clinical shift toward early and accurate serological diagnosis, and expanding automation of immunoassay-based autoantibody testing in clinical laboratories.
  • The global Rheumatoid Arthritis Diagnostics market is growing at a CAGR of 6.7% during the forecast period from 2026 to 2034.
  • By diagnostic test, the Rheumatoid Factor (RF) Tests segment dominated the Rheumatoid Arthritis Diagnostics market with a 38% share in 2025.
  • By technology, the Immunoassay segment dominated the Rheumatoid Arthritis Diagnostics market with a 41% share in 2025.
  • By disease stage, the Established Rheumatoid Arthritis segment dominated the Rheumatoid Arthritis Diagnostics market with a 64% share in 2025.
  • By sample type, the Blood/Serum segment dominated the Rheumatoid Arthritis Diagnostics market with a 78% share in 2025.
  • By end-users, the Diagnostic Laboratories segment dominated the Rheumatoid Arthritis Diagnostics market with a 39% share in 2025.
  • North America dominated the global Rheumatoid Arthritis Diagnostics market revenue with a 40% share in 2025, representing the highest regional market share globally.

Rheumatoid arthritis diagnostics encompass the serological, biochemical, and laboratory testing tools used to detect, confirm, and monitor rheumatoid arthritis, a chronic autoimmune disorder characterized by joint inflammation, synovial damage, and, if untreated, progressive disability. Because rheumatoid arthritis has no single confirmatory test, diagnosis relies on a combination of clinical evaluation and laboratory markers, including rheumatoid factor, anti-cyclic citrullinated peptide antibodies, C-reactive protein, and erythrocyte sedimentation rate, interpreted alongside imaging and physical examination. The market is organized by diagnostic test across rheumatoid factor tests, anti-cyclic citrullinated peptide antibody tests, C-reactive protein tests, erythrocyte sedimentation rate tests, and others; by technology, including immunoassay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, latex agglutination, and others; by disease stage, spanning early and established rheumatoid arthritis; by sample type, across blood/serum, plasma, synovial fluid, and others; and by end-users, led by hospitals and clinics, diagnostic laboratories, and specialty rheumatology clinics. Driven by rising disease prevalence, growing emphasis on early diagnosis to prevent irreversible joint damage, and the automation of autoantibody testing on high-throughput immunoassay and chemiluminescence platforms, rheumatoid arthritis diagnostics have become an essential component of the global rheumatology and autoimmune disease testing continuum.

Rheumatoid Arthritis Diagnostics Market Key Growth Drivers

  • The rising global prevalence of rheumatoid arthritis, affecting an estimated 0.5-1.0% of the adult population worldwide and disproportionately affecting women, is expanding the diagnosed and testable patient pool.
  • Growing clinical emphasis on early diagnosis is driving adoption of anti-CCP antibody testing, which offers high specificity for rheumatoid arthritis and enables treatment initiation before irreversible joint erosion occurs.
  • Diagnostic manufacturers are expanding multiplex and automated autoimmune panels, including Abbott's October 2025 FDA-cleared multiplex autoimmune panel detecting 12 autoantibodies simultaneously, improving testing breadth and laboratory efficiency.
  • Increasing automation of immunoassay and chemiluminescence platforms in clinical laboratories is reducing turnaround time and expanding testing capacity for rheumatoid factor and anti-CCP antibody assays.
  • Regulatory clearances and portfolio expansions by major diagnostics companies, including Roche's January 2026 expansion of its autoimmune testing platforms and Thermo Fisher's June 2026 FDA 510(k) clearance of the EliA CTD 13 Screen assay, are broadening the availability of advanced serological testing.
  • Growing awareness among rheumatologists and primary care physicians regarding the value of combined serological testing, alongside expanding insurance coverage for autoimmune panels, is increasing test utilization in developed and emerging markets.
  • The convergence of rising disease burden, technological automation, and expanding diagnostic portfolios is expected to sustain steady growth in the market through 2034.

Key Companies in Rheumatoid Arthritis Diagnostics Market

The competitive landscape is led by the following active manufacturers:

  • Abbott Laboratories
  • F. Hoffmann-La Roche
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Beckman Coulter
  • Werfen
  • Svar Life Science
  • Orgentec Diagnostika
  • EUROIMMUN

Factors Contributing to the Growth of the Rheumatoid Arthritis Diagnostics Market

Market Drivers

Rising Global Prevalence of Rheumatoid Arthritis

The most consistent driver of the Rheumatoid Arthritis Diagnostics market is the steadily rising global burden of the disease. Rheumatoid arthritis affects an estimated 0.5-1.0% of the adult population worldwide, with women accounting for roughly three-quarters of diagnosed cases, and incidence continues to climb alongside an aging global population and improved disease recognition. As more patients present with joint pain, stiffness, and swelling, primary care physicians and rheumatologists increasingly rely on serological testing, including rheumatoid factor and anti-CCP antibody assays, to confirm diagnosis and differentiate rheumatoid arthritis from other inflammatory and degenerative joint conditions. Because rheumatoid arthritis has no single definitive test, diagnostic laboratories often run panels combining multiple markers, further expanding testing volumes. As global disease prevalence continues to rise through 2034, the addressable population for diagnostic testing expands directly, anchoring sustained market growth.

Growing Emphasis on Early and Accurate Diagnosis

A structural shift toward early diagnosis is a central growth engine for the market. Clinical guidelines increasingly emphasize that early identification and treatment of rheumatoid arthritis, ideally within the first months of symptom onset, substantially reduces the risk of irreversible joint erosion and long-term disability. Anti-cyclic citrullinated peptide antibody tests, which offer high specificity and can be positive years before clinical symptoms fully manifest, are central to this early-detection strategy and are increasingly used alongside rheumatoid factor testing to improve diagnostic confidence. Rheumatologists and primary care physicians are adopting combined serological panels rather than single-marker testing to reduce false negatives in early-stage disease. As health systems continue to prioritize early intervention to reduce the long-term cost of disability and joint replacement, demand for sensitive and specific diagnostic testing rises correspondingly across the forecast period.

Market Restraints

Despite steady momentum, the Rheumatoid Arthritis Diagnostics market faces material constraints. The lack of a single definitive diagnostic test for rheumatoid arthritis means that no individual biomarker offers complete sensitivity and specificity; rheumatoid factor is present in other autoimmune conditions and even in healthy individuals, producing false positives, while anti-CCP antibodies, though more specific, can lack sensitivity in early-stage disease, requiring costlier combined panels and clinical correlation. Diagnostic delays remain common because early rheumatoid arthritis symptoms overlap with other inflammatory and degenerative joint conditions, and access to rheumatology specialists is limited in many regions, particularly in rural and low-resource settings. High costs of automated multiplex and chemiluminescence platforms constrain adoption among smaller laboratories and in price-sensitive emerging markets, while inconsistent reimbursement for advanced autoimmune panels outside major developed markets limits test utilization. Variability in assay performance across different manufacturers' anti-CCP and rheumatoid factor tests, as demonstrated in comparative diagnostic studies, complicates result interpretation and standardization across laboratories. Together, these diagnostic-accuracy, access, cost, and standardization barriers temper the pace of growth, even as the underlying drivers of rising disease prevalence and early-diagnosis emphasis remain firmly intact.

Rheumatoid Arthritis Diagnostics Market Segment Analysis

The rheumatoid arthritis diagnostics market by diagnostic test (rheumatoid factor (rf) tests, anti-cyclic citrullinated peptide (anti-ccp) antibody tests, c-reactive protein (crp) tests, erythrocyte sedimentation rate (esr) tests, and others), technology (immunoassay, enzyme-linked immunosorbent assay (elisa), chemiluminescence immunoassay (clia), latex agglutination, and others), disease stage (early rheumatoid arthritis and established rheumatoid arthritis), sample type (blood/serum, plasma, synovial fluid, others), end-users (hospitals & clinics, diagnostic laboratories, specialty rheumatology clinics, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Diagnostic Test

Dominant Subsegment: Rheumatoid Factor (RF) Tests.

The rheumatoid factor tests segment accounted for 38% of the Rheumatoid Arthritis Diagnostics market in 2025. Rheumatoid factor testing is the leading diagnostic test because it remains the most widely available, cost-effective, and clinically established first-line serological marker for rheumatoid arthritis, routinely ordered by primary care physicians and rheumatologists alike. Its long-standing inclusion in classification criteria, broad availability on latex agglutination, immunoturbidimetric, and immunoassay platforms, and low per-test cost sustain very high testing volumes across hospitals, clinics, and diagnostic laboratories worldwide. While anti-CCP antibody testing offers superior specificity and is the fastest-growing diagnostic test as clinicians prioritize early and accurate diagnosis, the sheer volume, affordability, and entrenched clinical use of rheumatoid factor testing secure the segment's leadership across the forecast period.

By Technology

Dominant Subsegment: Immunoassay.

The immunoassay segment accounted for 41% of the Rheumatoid Arthritis Diagnostics market in 2025. Immunoassay-based platforms, encompassing automated chemiluminescence and immunoturbidimetric formats, are the leading technology because they combine high throughput, strong analytical sensitivity, and full automation, allowing clinical laboratories to process large volumes of rheumatoid factor and anti-CCP antibody tests with minimal manual intervention. Their integration into core laboratory analyzers from major diagnostics manufacturers enables rapid turnaround and consistent standardization across testing sites. Chemiluminescence immunoassay is the fastest-growing technology as laboratories increasingly migrate from manual enzyme-linked immunosorbent assays toward fully automated platforms, while enzyme-linked immunosorbent assay and latex agglutination retain relevance in smaller laboratories and cost-sensitive markets. Nonetheless, the scale, automation, and platform integration advantages of immunoassay technology keep it the dominant category across the forecast period.

Rheumatoid Arthritis Diagnostics Market Region Analysis

Dominant Region: North America

North America accounted for 40% of the global Rheumatoid Arthritis Diagnostics market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature clinical laboratory infrastructure, high awareness of rheumatoid arthritis among physicians and patients, broad insurance coverage for autoimmune serology panels, and the concentrated presence of leading diagnostics manufacturers, particularly in the United States. North America benefits from early and widespread adoption of automated chemiluminescence and multiplex immunoassay platforms, supported by regulatory clearances such as Abbott's October 2025 multiplex autoimmune panel and Beckman Coulter's DxC 500i analyzer. High rheumatoid arthritis prevalence, strong reimbursement for laboratory testing, and the presence of extensive reference laboratory networks anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Rheumatoid Arthritis Diagnostics market. The region's elevated CAGR is driven by rising rheumatoid arthritis prevalence, expanding healthcare infrastructure, and growing diagnostic laboratory investment across China, Japan, India, South Korea, and Australia. China is expanding access to automated immunoassay testing and broadening insurance coverage for autoimmune panels, Japan is deepening adoption of advanced serological diagnostics within its aging population, and India is expanding low-cost, high-volume diagnostic laboratory networks that improve access to rheumatoid factor and anti-CCP testing. Government healthcare investment, growing rheumatology specialist training, and rising awareness of early diagnosis are accelerating adoption, while regional laboratories increasingly upgrade to automated, multiplex-capable platforms aligned with global standards. The combination of rising disease burden, infrastructure build-out, and improving diagnostic access positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 40% of the global Rheumatoid Arthritis Diagnostics market revenue in 2025. The United States dominates on the strength of its mature clinical laboratory infrastructure, broad reimbursement for autoimmune serology, and the concentrated presence of leading diagnostics manufacturers, while continued regulatory clearances for multiplex and automated immunoassay platforms reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by established regulatory frameworks, a strong base of specialized autoimmune diagnostics manufacturers including Werfen, Orgentec Diagnostika, and EUROIMMUN, and well-developed rheumatology referral networks. Ongoing assay standardization efforts and expanding automated testing adoption across Germany, France, the United Kingdom, Italy, and Spain reinforce the region's role in advanced autoimmune serology.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising disease prevalence, expanding diagnostic laboratory infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Expanding insurance coverage, rheumatology specialist training, and adoption of automated immunoassay platforms are accelerating regional testing volumes and laboratory modernization.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare and diagnostic laboratory infrastructure, rising awareness of rheumatoid arthritis and the value of early diagnosis, and gradual improvements in insurance coverage are broadening access, while partnerships with global diagnostics manufacturers support the build-out of regional testing capacity.

Rheumatoid Arthritis Diagnostics Market Competitive Landscape

The Rheumatoid Arthritis Diagnostics market is classified as Moderately Concentrated. A group of large, diversified in-vitro diagnostics companies with broad immunoassay and automation platforms, including Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific, anchor the top tier through global laboratory networks and integrated analyzer platforms, while specialized autoimmune diagnostics providers such as Werfen, Svar Life Science, Orgentec Diagnostika, and EUROIMMUN compete through deep rheumatology and autoimmune serology expertise, dedicated assay menus, and strong presence in reference and specialty laboratories, sustaining active competition across both broad-platform and specialized segments of the market.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Moderately concentrated, with large diversified diagnostics companies leading and specialized autoimmune-focused providers competing through deep rheumatology expertise.
  • Leading players: Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific anchor the top tier through broad immunoassay platforms and global laboratory reach.
  • Geographic reach: Leaders operate global, regionally distributed laboratory and distribution networks; Werfen operates directly in over 30 countries and through distributors in more than 100 territories.
  • Assay portfolio strength: Top players offer comprehensive rheumatoid factor, anti-CCP, CRP, and ESR testing menus across ELISA, chemiluminescence, and latex agglutination formats.
  • Platform automation: Ownership of fully automated, high-throughput immunoassay and clinical chemistry analyzers, including Beckman Coulter's DxC 500i and Thermo Fisher's Phadia 250, is a decisive competitive advantage.
  • Strategic partnerships: Alliances between specialized providers and biomarker discovery companies, such as Svar Life Science's partnership with Nimble Therapeutics focused on rheumatoid arthritis biomarkers, extend innovation reach.
  • Regulatory activity: Active regulatory clearances, including Abbott's multiplex autoimmune panel and Thermo Fisher's EliA CTD 13 Screen, continue to expand approved testing menus.
  • Manufacturing and R&D capabilities: In-house antigen and reagent development, automated ELISA and CLIA production, and dedicated autoimmune assay R&D are key competitive moats for specialized players such as Orgentec Diagnostika and EUROIMMUN.
  • Innovation focus: Multiplex autoantibody panels, chemiluminescence automation, point-of-care testing formats, and biomarker-based early-diagnosis assays.

Rheumatoid Arthritis Diagnostics Market Recent Developmental Activities

In June 2026, Thermo Fisher Scientific received FDA 510(k) clearance for its EliA CTD 13 Screen assay on the Phadia 250 platform, providing laboratories with a new option for systemic connective tissue disease and autoimmune testing. Strategic significance: Broadens Thermo Fisher's autoimmune serology menu and reinforces its automated immunoassay platform footprint in rheumatology testing.

In March 2026, Thermo Fisher Scientific expanded its autoimmune diagnostics portfolio with advanced immunoassay and laboratory testing solutions designed to improve detection and monitoring of autoimmune disorders, including rheumatoid arthritis. Strategic significance: Strengthens breadth of autoimmune testing offerings across global laboratory customers.

Rheumatoid Arthritis Diagnostics Market Segmentation

Rheumatoid Arthritis Diagnostics Market by Diagnostic Test

  • Rheumatoid Factor (RF) Tests
  • Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody Tests
  • C-Reactive Protein (CRP) Tests
  • Erythrocyte Sedimentation Rate (ESR) Tests
  • Others

Rheumatoid Arthritis Diagnostics Market by Technology

  • Immunoassay
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chemiluminescence Immunoassay (CLIA)
  • Latex Agglutination
  • Others

Rheumatoid Arthritis Diagnostics Market by Disease Stage

  • Early Rheumatoid Arthritis
  • Established Rheumatoid Arthritis

Rheumatoid Arthritis Diagnostics Market by Sample Type

  • Blood/Serum
  • Plasma
  • Synovial Fluid
  • Others

Rheumatoid Arthritis Diagnostics Market by End-Users

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Specialty Rheumatology Clinics
  • Others

Rheumatoid Arthritis Diagnostics Market by Geography

  • North America Rheumatoid Arthritis Diagnostics Market
  • United States Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Canada Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Mexico Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Europe Rheumatoid Arthritis Diagnostics Market
  • Germany Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • United Kingdom Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • France Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Italy Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Spain Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Rest of Europe Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Asia-Pacific Rheumatoid Arthritis Diagnostics Market
  • China Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Japan Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • India Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Australia Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • South Korea Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Rheumatoid Arthritis Diagnostics Market
  • Middle East Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • Africa Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
  • South America Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)

Key Takeaways from the Rheumatoid Arthritis Diagnostics Market Report Study

  • Market size analysis for the current Rheumatoid Arthritis Diagnostics market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global Rheumatoid Arthritis Diagnostics market.
  • Various opportunities available for competitors in the Rheumatoid Arthritis Diagnostics market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current Rheumatoid Arthritis Diagnostics market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for Rheumatoid Arthritis Diagnostics market growth in the future?

Target audience who can benefit from this Rheumatoid Arthritis Diagnostics market report study

  • Rheumatoid Arthritis Diagnostics product providers
  • Research organizations and consulting companies
  • Rheumatoid Arthritis Diagnostics -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Rheumatoid Arthritis Diagnostics
  • Various end-users who want to know more about the Rheumatoid Arthritis Diagnostics market and the latest technological developments in the Rheumatoid Arthritis Diagnostics market.

Frequently Asked Questions:

Q1. What is the growth rate of the Rheumatoid Arthritis Diagnostics market?

The Rheumatoid Arthritis Diagnostics market is projected to expand at a CAGR of 6.7% during the forecast period from 2026 to 2034.

Q2. What is the market size of the Rheumatoid Arthritis Diagnostics market?

The Rheumatoid Arthritis Diagnostics market is estimated at USD 3.15 billion in 2025 and is projected to reach USD 5.65 billion by 2034.

Q3. Which region dominates the Rheumatoid Arthritis Diagnostics market?

North America dominated the Rheumatoid Arthritis Diagnostics market with a 40% share of global revenue in 2025, supported by a mature clinical laboratory infrastructure, broad reimbursement for autoimmune serology testing, high physician and patient awareness, and the concentrated presence of leading diagnostics manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Rheumatoid Arthritis Diagnostics market?

The principal drivers are the rising global prevalence of rheumatoid arthritis; growing clinical emphasis on early and accurate diagnosis using anti-CCP antibody testing; expanding automation of immunoassay and chemiluminescence testing platforms; regulatory clearances and portfolio expansions such as Abbott's October 2025 multiplex autoimmune panel and Thermo Fisher's June 2026 EliA CTD 13 Screen clearance; and rising healthcare expenditure and diagnostic awareness.

Q5. Who are the major players in the Rheumatoid Arthritis Diagnostics market?

The major players include Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, Werfen, Svar Life Science, Orgentec Diagnostika, and EUROIMMUN, among other active providers profiled in the Competitive Landscape section. Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific lead through broad immunoassay platforms and global laboratory reach.

Table of Contents

1. Rheumatoid Arthritis Diagnostics Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumptions

2. Rheumatoid Arthritis Diagnostics Market Executive Summary

  • 2.1 Market at a Glance

3. Rheumatoid Arthritis Diagnostics Market Key Factors Analysis

  • 3.1 Rheumatoid Arthritis Diagnostics Market Drivers
    • 3.1.1 Rising Global Prevalence of Rheumatoid Arthritis
    • 3.1.2 Growing Emphasis on Early and Accurate Diagnosis
    • 3.1.3 Automation of Immunoassay Testing Platforms
    • 3.1.4 Regulatory Clearances and Portfolio Expansion
  • 3.2 Rheumatoid Arthritis Diagnostics Market Restraints and Challenges
    • 3.2.1 Lack of a Single Definitive Diagnostic Test
    • 3.2.2 Diagnostic Delays and Limited Specialist Access
    • 3.2.3 Cost and Reimbursement Constraints
  • 3.3 Rheumatoid Arthritis Diagnostics Market Opportunities
    • 3.3.1 Multiplex and Automated Panel Expansion
    • 3.3.2 Emerging-Market Diagnostic Laboratory Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1 United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Rheumatoid Arthritis Diagnostics Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Buyers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Rheumatoid Arthritis Diagnostics Market Assessment

  • 7.1 By Diagnostic Test
    • 7.1.1 Rheumatoid Factor (RF) Tests
    • 7.1.2 Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody Tests
    • 7.1.3 C-Reactive Protein (CRP) Tests
    • 7.1.4 Erythrocyte Sedimentation Rate (ESR) Tests
    • 7.1.5 Others
  • 7.2 By Technology
    • 7.2.1 Immunoassay
    • 7.2.2 Enzyme-Linked Immunosorbent Assay (ELISA)
    • 7.2.3 Chemiluminescence Immunoassay (CLIA)
    • 7.2.4 Latex Agglutination
    • 7.2.5 Others
  • 7.3 By Disease Stage
    • 7.3.1 Early Rheumatoid Arthritis
    • 7.3.2 Established Rheumatoid Arthritis
  • 7.4 By Sample Type
    • 7.4.1 Blood/Serum
    • 7.4.2 Plasma
    • 7.4.3 Synovial Fluid
    • 7.4.4 Others
  • 7.5 By End-Users
    • 7.5.1 Hospitals & Clinics
    • 7.5.2 Diagnostic Laboratories
    • 7.5.3 Specialty Rheumatology Clinics
    • 7.5.4 Others
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 United States Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.1.2 Canada Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.1.3 Mexico Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
    • 7.6.2 Europe
      • 7.6.2.1 Germany Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.2 United Kingdom Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.3 France Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.4 Italy Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.5 Spain Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.2.6 Rest of Europe Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 China Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.2 Japan Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.3 India Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.4 Australia Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.5 South Korea Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.3.6 Rest of Asia-Pacific Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
    • 7.6.4 Rest of World
      • 7.6.4.1 Middle East Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.4.2 Africa Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)
      • 7.6.4.3 South America Rheumatoid Arthritis Diagnostics Market Size in USD million (2023-2034)

8. Rheumatoid Arthritis Diagnostics Market Competitive Landscape

  • 8.1 Market Concentration and Structure
  • 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Rheumatoid Arthritis Diagnostics Market Startup Funding and Investment Trends

10. Rheumatoid Arthritis Diagnostics Market Company and Product Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Service Portfolio
    • 10.1.5 Strategic Initiatives / Entropy
  • 10.2 F. Hoffmann-La Roche
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Portfolio
    • 10.2.5 Strategic Initiatives / Entropy
  • 10.3 Siemens Healthineers
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Portfolio
    • 10.3.5 Strategic Initiatives / Entropy
  • 10.4 Thermo Fisher Scientific
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Portfolio
    • 10.4.5 Strategic Initiatives / Entropy
  • 10.5 Bio-Rad Laboratories
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Portfolio
    • 10.5.5 Strategic Initiatives / Entropy
  • 10.6 Beckman Coulter
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Portfolio
    • 10.6.5 Strategic Initiatives / Entropy
  • 10.7 Werfen
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Portfolio
    • 10.7.5 Strategic Initiatives / Entropy
  • 10.8 Svar Life Science
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Portfolio
    • 10.8.5 Strategic Initiatives / Entropy
  • 10.9 Orgentec Diagnostika
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Portfolio
    • 10.9.5 Strategic Initiatives / Entropy
  • 10.10 EUROIMMUN
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Portfolio
    • 10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Rheumatoid Arthritis Diagnostics Market in Global (2023-2034)
  • Table 2: Rheumatoid Arthritis Diagnostics Market in Global by Diagnostic Test (2023-2034)
  • Table 3: Rheumatoid Arthritis Diagnostics Market in Global by Technology (2023-2034)
  • Table 4: Rheumatoid Arthritis Diagnostics Market in Global by Disease Stage (2023-2034)
  • Table 5: Rheumatoid Arthritis Diagnostics Market in Global by Sample Type (2023-2034)
  • Table 6: Rheumatoid Arthritis Diagnostics Market in Global by End-Users (2023-2034)
  • Table 7: Rheumatoid Arthritis Diagnostics Market in Global by Geography (2023-2034)
  • Table 8: Rheumatoid Arthritis Diagnostics Market in North America (2023-2034)
  • Table 9: Rheumatoid Arthritis Diagnostics Market in the United States (2023-2034)
  • Table 10: Rheumatoid Arthritis Diagnostics Market in Canada (2023-2034)
  • Table 11: Rheumatoid Arthritis Diagnostics Market in Mexico (2023-2034)
  • Table 12: Rheumatoid Arthritis Diagnostics Market in Europe (2023-2034)
  • Table 13: Rheumatoid Arthritis Diagnostics Market in Germany (2023-2034)
  • Table 14: Rheumatoid Arthritis Diagnostics Market in United Kingdom (2023-2034)
  • Table 15: Rheumatoid Arthritis Diagnostics Market in France (2023-2034)
  • Table 16: Rheumatoid Arthritis Diagnostics Market in Italy (2023-2034)
  • Table 17: Rheumatoid Arthritis Diagnostics Market in Spain (2023-2034)
  • Table 18: Rheumatoid Arthritis Diagnostics Market in the Rest of Europe (2023-2034)
  • Table 19: Rheumatoid Arthritis Diagnostics Market in Asia-Pacific (2023-2034)
  • Table 20: Rheumatoid Arthritis Diagnostics Market in China (2023-2034)
  • Table 21: Rheumatoid Arthritis Diagnostics Market in Japan (2023-2034)
  • Table 22: Rheumatoid Arthritis Diagnostics Market in India (2023-2034)
  • Table 23: Rheumatoid Arthritis Diagnostics Market in Australia (2023-2034)
  • Table 24: Rheumatoid Arthritis Diagnostics Market in South Korea (2023-2034)
  • Table 25: Rheumatoid Arthritis Diagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Table 26: Rheumatoid Arthritis Diagnostics Market in the Rest of the World (2023-2034)
  • Table 27: Rheumatoid Arthritis Diagnostics Market in the Middle East (2023-2034)
  • Table 28: Rheumatoid Arthritis Diagnostics Market in Africa (2023-2034)
  • Table 29: Rheumatoid Arthritis Diagnostics Market in South America (2023-2034)
  • Table 30: Competitive Landscape
  • Table 31: Startup Funding and Investment Trends

List of Figures

  • Figure 1: Rheumatoid Arthritis Diagnostics Market Drivers
  • Figure 2: Rheumatoid Arthritis Diagnostics Market Restraints
  • Figure 3: Rheumatoid Arthritis Diagnostics Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis (US, EU, Japan, China)
  • Figure 6: Porter's Five Forces Analysis
  • Figure 7: Competitive Analysis
  • Figure 8: Rheumatoid Arthritis Diagnostics Market in Global (2023-2034)
  • Figure 9: Rheumatoid Arthritis Diagnostics Market in Global by Diagnostic Test (2023-2034)
  • Figure 10: Rheumatoid Arthritis Diagnostics Market in Global by Technology (2023-2034)
  • Figure 11: Rheumatoid Arthritis Diagnostics Market in Global by Disease Stage (2023-2034)
  • Figure 12: Rheumatoid Arthritis Diagnostics Market in Global by Sample Type (2023-2034)
  • Figure 13: Rheumatoid Arthritis Diagnostics Market in Global by End-Users (2023-2034)
  • Figure 14: Rheumatoid Arthritis Diagnostics Market in Global by Geography (2023-2034)
  • Figure 15: Rheumatoid Arthritis Diagnostics Market in North America (2023-2034)
  • Figure 16: Rheumatoid Arthritis Diagnostics Market in the United States (2023-2034)
  • Figure 17: Rheumatoid Arthritis Diagnostics Market in Canada (2023-2034)
  • Figure 18: Rheumatoid Arthritis Diagnostics Market in Mexico (2023-2034)
  • Figure 19: Rheumatoid Arthritis Diagnostics Market in Europe (2023-2034)
  • Figure 20: Rheumatoid Arthritis Diagnostics Market in Germany (2023-2034)
  • Figure 21: Rheumatoid Arthritis Diagnostics Market in United Kingdom (2023-2034)
  • Figure 22: Rheumatoid Arthritis Diagnostics Market in France (2023-2034)
  • Figure 23: Rheumatoid Arthritis Diagnostics Market in Italy (2023-2034)
  • Figure 24: Rheumatoid Arthritis Diagnostics Market in Spain (2023-2034)
  • Figure 25: Rheumatoid Arthritis Diagnostics Market in the Rest of Europe (2023-2034)
  • Figure 26: Rheumatoid Arthritis Diagnostics Market in Asia-Pacific (2023-2034)
  • Figure 27: Rheumatoid Arthritis Diagnostics Market in China (2023-2034)
  • Figure 28: Rheumatoid Arthritis Diagnostics Market in Japan (2023-2034)
  • Figure 29: Rheumatoid Arthritis Diagnostics Market in India (2023-2034)
  • Figure 30: Rheumatoid Arthritis Diagnostics Market in Australia (2023-2034)
  • Figure 31: Rheumatoid Arthritis Diagnostics Market in South Korea (2023-2034)
  • Figure 32: Rheumatoid Arthritis Diagnostics Market in Rest of Asia-Pacific (2023-2034)
  • Figure 33: Rheumatoid Arthritis Diagnostics Market in the Rest of the World (2023-2034)
  • Figure 34: Rheumatoid Arthritis Diagnostics Market in the Middle East (2023-2034)
  • Figure 35: Rheumatoid Arthritis Diagnostics Market in Africa (2023-2034)
  • Figure 36: Rheumatoid Arthritis Diagnostics Market in South America (2023-2034)
  • Figure 37: Competitive Landscape
  • Figure 38: Startup Funding and Investment Trends